betahistine dihydrochloride accord 24 mg tabletki
accord healthcare polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 24 mg
betahistine dihydrochloride aurovitas 16 mg tabletki
aurovitas pharma polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 16 mg
betahistine dihydrochloride aurovitas 8 mg tabletki
aurovitas pharma polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 8 mg
betahistine dihydrochloride aurovitas 24 mg tabletki
aurovitas pharma polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 24 mg
betahistine dihydrochloride accord 8 mg tabletki
accord healthcare polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 8 mg
betahistine dihydrochloride accord 16 mg tabletki
accord healthcare polska sp. z o.o. - betahistini dihydrochloridum - tabletki - 16 mg
levocetirizine dihydrochloride cipla 5 mg tabletki powlekane
cipla europe nv - levocetirizini dihydrochloridum - tabletki powlekane - 5 mg
sapropterin dipharma
dipharma arzneimittel gmbh - Сапроптерин дигидрохлорид - fenyloketonurie - inne przewodu pokarmowego i przemianę materii narzędzia, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Środki przeciwnowotworowe - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioedemas, dziedziczny - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.